ACPU
BMRN icon

Arrowgrass Capital Partners (US)’s BioMarin Pharmaceuticals BMRN Stock Holding History

Arrowgrass Capital Partners (US)’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-401
Closed -$5M – 520
2015
Q1 		$5M Buy
+401
New +$42.5K 0.08% 150

Other funds holding BMRN

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Arrowgrass Capital Partners (US)'s BMRN Position: Q3 2019 in Review

Arrowgrass Capital Partners (US) sold out of BioMarin Pharmaceuticals (BMRN) in Q3 2019, closing a stake of 196,478 shares — an estimated $16.8M sold.

Arrowgrass Capital Partners (US) first reported a position in BMRN in Q3 2013 and held it in 18 quarters. The position peaked at $34.4M in Q3 2013. 436 funds tracked by Wall St. Rank hold BMRN as of Q3 2019.

  • Arrowgrass Capital Partners (US) reported no remaining BioMarin Pharmaceuticals position as of Q3 2019 after selling out during the quarter.
  • Arrowgrass Capital Partners (US) sold 196,478 BioMarin Pharmaceuticals shares in Q3 2019, an estimated $16.8M.
  • Arrowgrass Capital Partners (US) first reported a position in BioMarin Pharmaceuticals in Q3 2013 and held it in 18 quarters.
  • Arrowgrass Capital Partners (US)'s BioMarin Pharmaceuticals position peaked at $34.4M in Q3 2013.
  • 436 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2019.

Based on Arrowgrass Capital Partners (US)'s 13F filing for Q3 2019, filed 14 Nov 2019.